Summit's Imfinzi win is real. The revenue isn't Summit's.

The market got the news it wanted: ivonescimab, the drug that turned Summit Therapeutics (NASDAQ: SMMT) into an $11 billion company, beat AstraZeneca's Imfinzi in a late-stage trial, and Summit stock jumped about 6.5% in a day. The good news is genuine. It is worth understanding precisely because the reason it is good is not what the headline implies.

That trial was run in China, by Akeso — the Chinese company that invented the drug and kept the rights to sell it there. Summit never acquired China. A win in a market Summit cannot sell into is real evidence. It is not Summit's revenue. Those are different financial events, and the stock's whole story is compressed inside that difference.

The win, precisely

The study is HARMONi-GI1, a Phase 3 for patients with advanced biliary tract cancer — tumors of the bile ducts and gallbladder, a nastier and much smaller corner of oncology than the lung setting where ivonescimab made its name. It compared ivonescimab plus chemotherapy head-to-head against durvalumab (Imfinzi) plus chemotherapy, the regimen international guidelines call the global gold standard in this disease. The trial met its primary endpoint of overall survival at a pre-specified interim analysis, with statistically significant and clinically meaningful results, and also hit the key secondary endpoints on progression-free survival and response rates. The specific survival numbers have not been released; they will come at a future medical congress.

The historical context gives the win its weight. This is the first known Phase 3 trial in advanced biliary tract cancer in which any drug has beaten an anti-PD-(L)1-plus-chemotherapy regimen on overall survival — Imfinzi itself had set that standard with the TOPAZ-1 study. It is also the first Phase 3 success for ivonescimab outside lung cancer, and it makes a clean sweep: five readouts, five wins, four of them in lung.

Who owns what

Akeso is not Summit's competitor; it is Summit's supplier and landlord. The drug is a single molecule read two ways. In the territories Summit licenses — the United States, Canada, Europe, Japan, and later Latin America, the Middle East and Africa — it is called SMT112 and belongs to Summit. In China and the rest of the world it is AK112 and belongs to Akeso.

The terms show who holds the leverage. In December 2022 Summit paid $500 million for its ex-China rights and can owe up to another $4.5 billion in milestones, plus a low-double-digit royalty on everything it eventually sells. Akeso gave up geography, not economics: it kept the commercial franchise in China, where ivonescimab is already approved for lung cancer and Akeso reported a record RMB 3.03 billion of commercial sales revenue for 2025, and it collects a percentage of whatever Summit earns elsewhere.

So a Chinese trial win, achieved on Akeso's budget in Akeso's market, flows first to Akeso's revenue line. Summit itself has said the readout is single-region and does not currently support approval in its own territories. Biliary tract cancer is not even in Summit's announced ex-China Phase 3 program, which is built around lung, colorectal, bladder and head-and-neck trials. Today's jump is therefore a read-through — evidence about the mechanism, not a claim on this result.

The inconvenient symmetry

Here is the number every Summit shareholder should think about slowly. After the pop, Summit's market capitalization is roughly $11.4 billion. Akeso's is about HK$87 billion — almost exactly $11 billion. Two companies, same price tag, wildly different ownership.

Akeso's side of the ledger includes an outright China franchise that is already selling, royalties on every dollar Summit ever books, seven marketed drugs, and a full pipeline of its own. Summit's side is an exclusive option on one drug that has never been approved in a single Summit territory, is not yet generating revenue, and pays royalties out of whatever it earns.

The market is valuing Summit's slice of the pie at about the same price as Akeso's whole bakery. That is either a spectacularly cheap Akeso or an exceptionally expensive Summit — and for an owner of SMMT it is a standing reminder that today's China win enriched the partner that already has the revenue, while the partner that rose in the headlines got a vote of confidence it cannot immediately cash.

What actually moves the price

The crowd has already demonstrated that it understands the real bet. This is not a stock riding a wave of wins; it is a stock that ran to roughly $29, fell to about $12, and still trades near half its 52-week high — down roughly 19% year to date even after this week's pop. The de-rating happened while the drug was winning, because the number that governs the price is not the win count. It is the approval Summit can actually sell into, and the survival edge it proves in Western patients.

The near-term calendar makes the point. Summit's first shot at a U.S. approval — the EGFR-mutated lung cancer application based on the global HARMONi trial — has a Food and Drug Administration PDUFA decision date of November 14. The supporting data were published in The Lancet Oncology within the past week, showing the drug roughly halved the risk of progression; the survival readout missed the formal statistical bar on the first look but showed a clearer benefit on follow-up, with a hazard ratio of 0.78 overall and 0.70 among North American patients. That matters, because China-only results have never proven a drug in the West, and this is the evidence that they can be translated.

The bigger prize is still a year away. HARMONi-3 is the global Phase 3 where ivonescimab plus chemotherapy takes on Merck's Keytruda — the reigning standard for first-line metastatic lung cancer — in the same tumor type, in Summit's own markets. Summit guides a squamous-cell readout in the second half of 2026 and the weightier non-squamous analysis in the first half of 2027. This is where a Chinese winner becomes (or fails to become) a Western blockbuster, and no biliary tract win brings it closer than a week.

All of it is being paid for with money the company does not earn. Summit reported about $691 million of cash and investments at the end of June, while burning roughly $150 million per quarter in non-GAAP operating expenses — near a $600 million annual run rate — and replenishing the tank through an at-the-market share facility that raised about $230 million in the second quarter and more since. Every ATM share is a claim on the same upside the bulls are already paying full freight for.

The honest bull case

None of this makes the rally wrong. A mechanism that wins in four lung settings and then in the gut is behaving like the biology is the edge, not the trial design or the market's sympathy. And the China study is the cheapest possible way to de-risk the identical mechanism Summit's ex-China program depends on — Akeso absorbs the cost, Summit reads the answer for free. The reasonable bull position is that the drug's biology keeps refusing to fail, which is precisely the precondition HARMONi-3 needs. Take that seriously.

The discipline is to give today's read-through its modest weight and watch the two dates that actually pay the bill. If the November FDA decision clears without drama, and HARMONi-3 shows a meaningful survival edge over Keytruda in the big non-squamous population, then this week's reaction will look like the cheap preview of a much larger story. If HARMONi-3 lands with a modest number, or a launch is delayed while the ATM keeps printing shares, a no-revenue company with an $11 billion market value has a great deal of room to fall — and the near-parity with its royalties-collecting licensor is the reference for how lopsided that risk is.

Repeating the headline costs nothing and remains comfortable until the two real readouts arrive. That is exactly why the comfortable version stays cheap. The crowd can be right that the drug wins and still lose on the timing, the geography, and the price of the slice it bought. The win belongs to Akeso today; what Summit's shareholders own is a bet on whether it becomes theirs.